Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Diabetic Macular Edema
Biotech
Merck sees pivotal victory for $3B eye disease prospect
Merck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema drug candidate.
Nick Paul Taylor
Sep 24, 2026 8:15am
Roche drops lupus TCE, retains autoimmune cell therapy interest
Jul 23, 2026 4:51am
Ollin hauls in $330M for Vabysmo challenger's ph. 3 gauntlet
Jun 24, 2026 7:00am
BioCryst scraps eye drug to focus on rare diseases
May 6, 2026 10:40am
Ollin eyes phase 3 after topping Vabysmo in early-stage trial
Jan 8, 2026 3:20pm
Otsuka pens $420M deal for Asia rights to 4DMT gene therapy
Oct 31, 2025 5:09am
